Calcium/Calmodulin-Dependent Kinase IV Facilitates the Recruitment of Interleukin-17-Producing Cells to Target Organs Through the CCR6/CCL20 Axis in Th17 Cell-Driven Inflammatory Diseases.
Calcium/Calmodulin-Dependent Kinase IV Facilitates the Recruitment of Interleukin-17-Producing Cells to Target Organs Through the CCR6/CCL20 Axis in Th17 Cell-Driven Inflammatory Diseases.
复制标题
DOI:
10.1002/art.39665
复制
发表时间:
2016-08
期刊:
影响因子:
--
通讯作者:
Tsokos GC
中科院分区:
文献类型:
--
作者:
Koga T;Otomo K;Mizui M;Yoshida N;Umeda M;Ichinose K;Kawakami A;Tsokos GC
The recruitment of IL-17-producing T helper (Th17) cells to inflammatory sites has been implicated in the development of organ damage in inflammatory and autoimmune diseases including systemic lupus erythematosus (SLE). To define the mechanism of CaMK4 activation on Th17-cell recruitment to target tissues, we performed anti-glomerular basement membrane antibody-induced glomerulonephritis (AIGN) experiments in mice and studied samples from patients with SLE. We induced experimental AIGN in Camk4-sufficient or -deficient mice and compared histology, Th17-related chemokine expression and numbers of IL-17-producing cells in the kidneys. We also evaluated the efficacy of the CaMK4 antagonist KN-93 in alter AIGN induced kidney disease. The expression of CCR6 in memory CD4 T cells before AIGN induction was analyzed by flow cytometry. We investigated the correlation between CCR6 expression in the peripheral blood and the severity of glomerulonephritis in patients with SLE. Camk4-deficient mice displayed less glomerular injury after the induction of AIGN. Kidney infiltration by IL-17-producing CD4 T cells along with CCR6 and CCL20 expression were significantly decreased in Camk4-deficient mice. Similarly, the KN-93 treatment of mice prior to exposure to AIGN improved the clinical and pathological finings. The expression and function of CCR6 in memory CD4 T cells in the peripheral blood was decreased in the Camk4-deficient mice. The expression of CCR6 correlated positively with the severity of organ damage in SLE patients. Our results indicate that CaMK4 represents a novel therapeutic strategy for the treatment of Th17 cell-mediated tissue damage in inflammatory diseases.